617 results on '"Herr, Wolfgang"'
Search Results
2. Efficacy and safety of ruxolitinib in the treatment of chronic graft-versus-host disease: a retrospective analysis
3. Ruxolitinib for the treatment of acute graft-versus-host disease: a retrospective analysis
4. The WERA cancer center matrix: Strategic management of patient access to precision oncology in a large and mostly rural area of Germany
5. Analysis of long-term mortality after total body irradiation-based and melphalan-based chemotherapy conditioning for acute myeloid leukemia
6. Characteristics and outcome of patients with small bowel adenocarcinoma (SBA)
7. Magnetic CAR T cell purification using an anti-G4S linker antibody
8. Virus-reactive T cells expanded in aplastic anemia eliminate hematopoietic progenitor cells by molecular mimicry
9. The microbial metabolite desaminotyrosine enhances T-cell priming and cancer immunotherapy with immune checkpoint inhibitors
10. Targeting nucleic acid sensors in tumor cells to reprogram biogenesis and RNA cargo of extracellular vesicles for T cell-mediated cancer immunotherapy
11. Reg3α concentrations at day of allogeneic stem cell transplantation predict outcome and correlate with early antibiotic use
12. Second Cancer After Additive Chemotherapy in Patients With Colon Cancer
13. Impact of chronic graft-versus-host disease on quality of life and cognitive function of long-term transplant survivors after allogeneic hematopoietic stem cell transplantation with total body irradiation
14. Donor regulatory T cells rapidly adapt to recipient tissues to control murine acute graft-versus-host disease
15. Novel high-resolution contrast agent ultrasound techniques HiFR CEUS and SR CEUS in combination with shear wave elastography, fat assessment and viscosity of liver parenchymal changes and tumors
16. Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies
17. Retrospective analysis of the incidence and outcome of late acute and chronic graft-versus-host disease—an analysis from transplant centers across Europe
18. The WERA Cancer Center Matrix: Strategic Management of Patient Access to Precision Oncology in a Large and Mostly Rural Area of Germany
19. Strain specific differences in vitamin D3 response: impact on gut homeostasis
20. Entwicklung eines Screening-Workflows zur Erkennung von Patientenbedürfnissen in einer interdisziplinären onkologischen Tagesklinik
21. Incidence and Outcome of Atypical Manifestations of Chronic Graft-versus-Host Disease: Results From a Retrospective Single-Center Analysis
22. Abatacept as salvage therapy in chronic graft-versus-host disease—a retrospective analysis
23. Ectopic PU.1 Expression Provides Chimeric Antigen Receptor (CAR) T Cells with Innate Cell Capacities Including IFN-β Release.
24. Sex-Dependent T Cell Dysregulation in Mice with Diet-Induced Obesity.
25. D-2-hydroxyglutarate supports a tolerogenic phenotype with lowered major histocompatibility class II expression in non-malignant dendritic cells and acute myeloid leukemia cells
26. Bacteria and bacteriophage consortia are associated with protective intestinal metabolites in patients receiving stem cell transplantation
27. 1,25-dihydroxyvitamin-D3 but not the clinically applied marker 25-hydroxyvitamin-D3 predicts survival after stem cell transplantation
28. Color Mapping using Ultrasound System-integrated Perfusion Software for Evaluation of Focal Liver Lesions: A Possible First Step for More Independent Reading
29. Cyclophosphamide for salvage therapy of chronic graft-versus-host disease: a retrospective analysis
30. IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis
31. Mikrobiom und Immuntherapien bei Tumorerkrankungen
32. Tumorvakzine
33. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD
34. Low-dose azacitidine, pioglitazone and all-trans retinoic acid is safe in patients aged ≥ 60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA): results of the safety run-in phase
35. Allogeneic Cell Therapy
36. Long-term follow-up of rituximab in treatment of chronic graft-versus-host disease—single center experience
37. Immuntherapien in der Hämatologie und Onkologie
38. Non-invasive diagnosis of acute intestinal graft-versus-host disease by a new scoring system using ultrasound morphology, compound elastography, and contrast-enhanced ultrasound
39. Random gene sets in predicting survival of patients with hepatocellular carcinoma
40. Restrictive Versus Permissive Use of Broad-spectrum Antibiotics in Patients Receiving Allogeneic Stem Cell Transplantation and With Early Fever Due to Cytokine Release Syndrome: Evidence for Beneficial Microbiota Protection Without Increase in Infectious Complications
41. Intestinal IgA-positive plasma cells are highly sensitive indicators of alloreaction early after allogeneic transplantation and associate with both graft-versus-host disease and relapse-related mortality
42. Microbiota Disruption Induced by Early Use of Broad-Spectrum Antibiotics Is an Independent Risk Factor of Outcome after Allogeneic Stem Cell Transplantation
43. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
44. CAR T-cells targeting FLT3 have potent activity against FLT3−ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib
45. Apheresis for chimeric antigen receptor T‐cell production in adult lymphoma patients
46. All-oral low-dose chemotherapy TEPIP is effective and well-tolerated in patients with peripheral T-cell lymphoma
47. IRF4 downregulation improves sensitivity and endurance of CAR T cell functional capacities
48. Supplementary Figure 1 from Superior Antitumor In vitro Responses of Allogeneic Matched Sibling Compared with Autologous Patient CD8+ T Cells
49. Supplementary Figure 2 from Superior Antitumor In vitro Responses of Allogeneic Matched Sibling Compared with Autologous Patient CD8+ T Cells
50. Supplementary Figure Legends 1-2 from Superior Antitumor In vitro Responses of Allogeneic Matched Sibling Compared with Autologous Patient CD8+ T Cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.